Related Experiment Video
Updated: Aug 14, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Therapeutic strategies for the treatment of neuroblastoma
Elzbieta Izbicka1, Tadeusz Izbicki
1Institute for Drug Development, Cancer Therapy and Research Center, 14960 Omicron Drive, San Antonio, TX 78245, USA. eizbicka@idd.org
Abstract:
Neuroblastoma, the most common extracranial solid tumor in children, has a highly heterogeneous clinical presentation and course. Current risk-based therapy is usually effective in patients who have intermediate risk features, however, intensive treatment of advanced neuroblastoma in children over two years of age is far from satisfactory. Current therapeutic approaches include the optimization of pharmacokinetic and pharmacodynamic properties of conventional agents, as well as the development of novel targeted drugs, such as signal transduction and angiogenesis inhibitors, apoptosis/differentiation stimulators and immunotherapeutics. This review provides an overview of current treatment options and future perspectives for the therapy and prevention of neuroblastoma.
Insights
Neuroblastoma treatment is improving, but advanced cases in children over two require better therapies. This review covers current options and future directions for neuroblastoma treatment and prevention.
Area of Science:
- Pediatric Oncology
- Cancer Therapeutics
- Tumor Biology
Background:
- Neuroblastoma is a common childhood extracranial solid tumor with variable clinical outcomes.
- Current risk-based therapy is effective for intermediate-risk neuroblastoma.
- Advanced neuroblastoma in children over two years old presents significant treatment challenges.
Purpose of the Study:
- To review current treatment strategies for neuroblastoma.
- To explore future therapeutic perspectives for neuroblastoma.
- To discuss prevention of neuroblastoma.
Main Methods:
- Literature review of current and emerging neuroblastoma therapies.
- Analysis of pharmacokinetic and pharmacodynamic optimization of conventional agents.
- Evaluation of novel targeted drug development, including signal transduction inhibitors, angiogenesis inhibitors, apoptosis/differentiation stimulators, and immunotherapeutics.
Main Results:
- Current treatments show limitations in advanced pediatric neuroblastoma.
- Novel targeted therapies show promise for improved outcomes.
- Optimization of existing treatments is an ongoing area of research.
Conclusions:
- Further research is needed to improve outcomes for high-risk neuroblastoma.
- Targeted therapies and immunotherapies represent promising future directions.
- A multi-faceted approach is essential for effective neuroblastoma therapy and prevention.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...